NCT06427811 - Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Interventions

DRUG

Asciminib

Film-coated tablets with 40 mg dose strength taken orally

Trial Locations (10)

Novartis Investigative Site, Ahmedabad

Novartis Investigative Site, Ahmedabad

Novartis Investigative Site, Pune

Novartis Investigative Site, New Delhi

Novartis Investigative Site, Hyderabad

Novartis Investigative Site, Bengaluru

Novartis Investigative Site, Kolkata

Novartis Investigative Site, Cuttack

Novartis Investigative Site, Guwahati

Novartis Investigative Site, Trivandrum